{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:10:55Z","timestamp":1794438655130,"version":"4.9.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cells have demonstrated clinical benefit in patients with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL). We undertook a multicenter clinical trial to determine toxicity, feasibility, and response for this therapy. A total of 25 pediatric\/young adult patients (age, 1-22.5 years) with R\/R B-ALL were treated with 19-28z CAR T cells. Conditioning chemotherapy included high-dose (3 g\/m2) cyclophosphamide (HD-Cy) for 17 patients and low-dose (\u22641.5 g\/m2) cyclophosphamide (LD-Cy) for 8 patients. Fifteen patients had pretreatment minimal residual disease (MRD; &amp;lt;5% blasts in bone marrow), and 10 patients had pretreatment morphologic evidence of disease (\u22655% blasts in bone marrow). All toxicities were reversible, including severe cytokine release syndrome in 16% (4 of 25) and severe neurotoxicity in 28% (7 of 25) of patients. Treated patients were assessed for response, and, among the evaluable patients (n = 24), response and peak CAR T-cell expansion were superior in the HD-Cy\/MRD cohorts, as compared with the LD-Cy\/morphologic cohorts without an increase in toxicity. Our data support the safety of CD19-specific CAR T-cell therapy for R\/R B-ALL. Our data also suggest that dose intensity of conditioning chemotherapy and minimal pretreatment disease burden have a positive impact on response without a negative effect on toxicity. This trial was registered at www.clinicaltrials.gov as #NCT01860937.<\/jats:p>","DOI":"10.1182\/blood.2019001641","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T13:17:06Z","timestamp":1571404626000},"page":"2361-2368","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":258,"title":["Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-9956","authenticated-orcid":false,"given":"Kevin J.","family":"Curran","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Margossian","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Kernan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Division of Hematology\/Oncology, Boston Children's Hospital, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Forlenza","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinherz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Boulad","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Cancio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Kung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Khakoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medical College, New York, NY;"},{"name":"Department of Neurology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Szenes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Heller","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Senechal","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Riviere","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine,"},{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2020081112242395300_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"2020081112242395300_B2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"2020081112242395300_B3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2020081112242395300_B4","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2020081112242395300_B5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2020081112242395300_B6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","article-title":"Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group","volume":"47","author":"von Stackelberg","year":"2011","journal-title":"Eur J Cancer"},{"issue":"15","key":"2020081112242395300_B7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.2014.60.3449","article-title":"Chimeric antigen receptor T cells for cancer immunotherapy","volume":"33","author":"Curran","year":"2015","journal-title":"J Clin Oncol"},{"issue":"224","key":"2020081112242395300_B8","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"2020081112242395300_B9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"9967","key":"2020081112242395300_B10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"355","key":"2020081112242395300_B11","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"25","key":"2020081112242395300_B12","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020081112242395300_B13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2020081112242395300_B14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"177","key":"2020081112242395300_B15","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"2","key":"2020081112242395300_B16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J Immunother"},{"issue":"18, pt 1","key":"2020081112242395300_B17","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020081112242395300_B18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020081112242395300_B19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020081112242395300_B20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2008.000414","article-title":"Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting","volume":"94","author":"Irving","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2020081112242395300_B21","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"2020081112242395300_B22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2020081112242395300_B23","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020081112242395300_B24","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/blood.2020008394","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/26\/2361\/1752672\/bloodbld2019001641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/26\/2361\/1752672\/bloodbld2019001641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T20:02:20Z","timestamp":1597176140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/26\/2361\/409163\/Toxicity-and-response-after-CD19specific-CAR-Tcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":24,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001641","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]}}}